New leukemia drug tested in Real-World chinese patients
NCT ID NCT07375355
Summary
This study observes how well the drug asciminib works and how safe it is for adults newly diagnosed with a chronic form of blood cancer called CML. It will follow 200 patients in China who are starting asciminib treatment in real-world hospital settings, not a tightly controlled trial. The main goal is to see how many patients achieve a strong reduction in cancer markers after one year of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGWuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.